{"id":752049,"date":"2023-04-27T09:04:17","date_gmt":"2023-04-27T13:04:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"modified":"2023-04-27T09:04:17","modified_gmt":"2023-04-27T13:04:17","slug":"nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","title":{"rendered":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">FORT LEE, NJ, April  27, 2023  (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (\u201cNuvectis\u201d, \u201cCompany\u201d), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:18.7%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Event<\/td>\n<td style=\"width:81.3%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">H.C. Wainwright BioConnect Investor Conference at NASDAQ<\/td>\n<\/tr>\n<tr>\n<td style=\"width:18.7%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Date<\/td>\n<td style=\"width:81.3%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">May 2<sup>nd<\/sup>, 2022<\/td>\n<\/tr>\n<tr>\n<td style=\"width:18.7%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Time<\/td>\n<td style=\"width:81.3%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">12:00 PM Eastern Time <\/td>\n<\/tr>\n<tr>\n<td style=\"width:18.7%;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Link<\/td>\n<td style=\"width:81.3%;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"https:\/\/journey.ct.events\/view\/d4c831b5-30c2-446a-b4f3-259ffcfe5d94\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n              <u>https:\/\/journey.ct.events<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>About Nuvectis Pharma <\/strong>\n      <\/p>\n<p align=\"justify\">Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical-stage, oral small molecule under development for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and additional solid tumor types. The United States Food and Drug Administration (\u201cFDA\u201d) granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma. NXP900 is a novel, small molecule SRC\/YES1 kinase inhibitor with an Investigational New Drug (\u201cIND\u201d) application pending.<\/p>\n<p align=\"justify\">\n        <strong>Nuvectis Pharma Contact:<\/strong>\n      <\/p>\n<p>Ron Bentsur<br \/> Chairman, Chief Executive Officer and President <br \/> Tel: 201-614-3151<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xY3cQF_NdWqZTR9o7bEjXnzpD6YscV34pNmlbPE4HYvOor0bLbD44Xj2sfCRbtPOanLmgaMZSwRnLXtZf4D60c7QDBLQ_djR0HoSjpHYWr0=\" rel=\"nofollow noopener\" target=\"_blank\"><u>rbentsur@nuvectis.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contact: <\/strong>\n      <\/p>\n<p>Christopher M. Calabrese <br \/> LifeSci Advisors <br \/> Tel: 917-680-5608<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j-3sQQ6ZYwd2AFGNtoM-lFZ5_uHOq94xHmG-mqabD4ADksxJ8inqU8wD3pSBnexrX18cJlig3407gGcIk8GT0XhKPN5aolp9ZBkudbtPFVVgjlBDjGUqR58IKJXG7aSA\" rel=\"nofollow noopener\" target=\"_blank\"><u>ccalabrese@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Yjg5NDIxZDItZDFjNy00NzhlLWFmOGQtOWQwNmY5MWMyM2FlLTUwMDA4MjgxNw==\/tiny\/Nuvectis-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (\u201cNuvectis\u201d, \u201cCompany\u201d), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright BioConnect Investor Conference at NASDAQ Date May 2nd, 2022 Time 12:00 PM Eastern Time Link https:\/\/journey.ct.events About Nuvectis Pharma Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752049","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (\u201cNuvectis\u201d, \u201cCompany\u201d), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright BioConnect Investor Conference at NASDAQ Date May 2nd, 2022 Time 12:00 PM Eastern Time Link https:\/\/journey.ct.events About Nuvectis Pharma Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two &hellip; Continue reading &quot;Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T13:04:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference\",\"datePublished\":\"2023-04-27T13:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"},\"wordCount\":234,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\",\"name\":\"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\",\"datePublished\":\"2023-04-27T13:04:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","og_description":"FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (\u201cNuvectis\u201d, \u201cCompany\u201d), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright BioConnect Investor Conference at NASDAQ Date May 2nd, 2022 Time 12:00 PM Eastern Time Link https:\/\/journey.ct.events About Nuvectis Pharma Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two &hellip; Continue reading \"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T13:04:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference","datePublished":"2023-04-27T13:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"},"wordCount":234,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/","name":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==","datePublished":"2023-04-27T13:04:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjgwNSM1NTYwODY0IzUwMDA4MjgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-present-at-the-h-c-wainwright-bioconnect-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752049"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752049\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}